EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

House Dust Mite Allergy - Pipeline Review, H1 2017

  • ID: 4091117
  • Report
  • February 2017
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Stallergenes Greer plc
  • MORE
House Dust Mite Allergy - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2017, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 2 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • HAL Allergy BV
  • Stallergenes Greer plc
  • MORE
Introduction

House Dust Mite Allergy - Overview

House Dust Mite Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

House Dust Mite Allergy - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

House Dust Mite Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Circassia Pharmaceuticals Plc

HAL Allergy BV

Stallergenes Greer plc

House Dust Mite Allergy - Drug Profiles

Acarovac Quattro - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AllerDM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

House Dust Mite Allergy - Dormant Projects

House Dust Mite Allergy - Discontinued Products

House Dust Mite Allergy - Product Development Milestones

Featured News & Press Releases

Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval

Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis

Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX

Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA

Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet

Apr 05, 2016: Stallergenes Greer Announces The Approval Of Actair In Australia

Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France

Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark

Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan

Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan

Jun 09, 2015: ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal

Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet

Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet

Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study

Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for House Dust Mite Allergy, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1

House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H1

House Dust Mite Allergy - Pipeline by Anergis SA, H1

House Dust Mite Allergy - Pipeline by Biomay AG, H1

House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1

House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1

House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H1

House Dust Mite Allergy - Dormant Projects, H1

House Dust Mite Allergy - Discontinued Products, H1

List of Figures:

Number of Products under Development for House Dust Mite Allergy, H1

Number of Products under Development by Companies, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Stallergenes Greer plc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll